Carcinomas of the gallbladder and biliary system are rare, with an estimated 8,570 cases occurring in the United States in 2006. Because the majority of patients with biliary cancers present with unresectable or metastatic disease, the overall 5-year survival rate is less than 10%.[2,3] Surgery is the only potentially curative treatment for patients with biliary carcinoma; however, only 10% to 35% of patients are potential candidates for surgery at presentation.[4-6] In resected patients, outcome is closely associated with the pathologic findings of depth of tumor penetration and nodal metastases.
For patients resected for cure, the prognosis remains poor with high local failure rates and associated morbidity and mortality.[7,8] Given these poor outcomes, further therapy should be considered in management. However, the role of adjuvant radiation therapy and chemotherapy in resected patients is poorly defined given the rarity of this malignancy, low resection rates, and physician's therapeutic nihilism.
Importance of Local Tumor Control
Surgery is the only curative treatment modality in the management of patients with primary carcinoma of the gallbladder and bile duct cancer. Unfortunately, this subset constitutes only 10% to 35% of patients, with the overwhelming majority of patients presenting with locally advanced or metastatic disease. In patients undergoing "curative" resection, approximately half will experience local recurrence, resulting in death from biliary obstruction, sepsis, and/or liver failure. Therefore, patients with gallbladder and biliary carcinomas are frequently treated palliatively. Survival rates are poor, ranging from 2 to 3 months in patients receiving medical management alone, 6 to 12 months for those undergoing surgical palliation, and 12 to 22 months for resected patients. Overall 5-year survival remains dismal at less than 10%.
The optimal radiation dose and schedule in the adjuvant and "definitive" treatment of biliary malignancies is unknown. Current practice guidelines are derived from nonrandomized and single-institution experiences, with selection bias favoring high-dose treatment in good performance patients.[11,12]
Investigators from Hospital Lyon in France reported that patients receiving doses ≥ 40 Gy experienced median survivals of 22 months vs 10 months in patients receiving ≤ 35 Gy. Similarly, University of Pittsburgh investigators found that patients receiving radiation doses ≥ 45 Gy had improved median survival compared to those receiving < 45 Gy (11 vs 4.4 months). Similar data were reported from Thomas Jefferson University investigators who retrospectively stratified patients by total radiation dose ≤ 55 Gy or > 55 Gy. In this study, patients received combined external-beam radiation therapy (EBRT) as well as iridium (Ir)-192 brachytherapy. For patients receiving ≤ 55 Gy, median survival was 6 months and the 2-year survival rate was 0%, whereas for patients treated to > 55 Gy, these figures were 24 months and 48%. Median survival increased with escalating doses.
In contrast, investigators from the University of Amsterdam showed no benefit to doses > 55 Gy compared to patients receiving ≤ 55 Gy. Interpretation of these study results are complicated by heterogeneous disease stages, patient performance status, and variety of radiation therapy techniques and doses.
The role of radiation therapy for patients with resected cholangiocarcinoma is controversial. Pattern-of-failure analyses suggest that local failure following resection is common and the use of adjuvant radiation therapy is rational. Single-institution studies have attempted to clarify the role of adjuvant EBRT in resected patients and are discussed below.
An early study from the Massachusetts General Hospital reported the results of 13 patients following resection with curative intent. Patients receiving radiation therapy after surgery experienced a longer median survival (32 months) vs the nontreated cohort (13 months). Duke University investigators recently analyzed the outcome of 22 patients with localized gallbladder carcinoma undergoing resection and adjuvant radiation therapy. Patients undergoing radical resection had improved survival compared to patients undergoing a simple cholecystectomy. Estimated 5-year survival for the entire cohort was 37%, which compared favorably to reported surgery alone results for similar patients.
An EORTC (European Organization for Research and Treatment of Cancer) series retrospectively reviewed 112 patients with Klatskin tumors (tumors arising at the common hepatic duct bifurcation) and found a statistically improved survival in patients treated with resection and postoperative radiotherapy vs those with resection only (median survival: 19 vs 8.3 months; 3-year survival: 31% vs 10%).
Investigators from Johns Hopkins Hospital described 96 patients with proximal cholangiocarcinoma treated surgically (41% curative resection, 14% noncurative resection, 45% palliative stenting). Overall, 66% of patients received postoperative EBRT. Patients undergoing gross total or subtotal resection had improved survival vs patients undergoing stenting only. The 1-, 3-, and 5-year survival rates in the resection group were 66%, 21%, and 8%, respectively, compared to 27%, 6%, and 0%, respectively, in the stenting-alone group. Improved 2-year survival was observed in stented patients receiving EBRT vs patients treated with stent only (10% vs 0%). Additionally, 5-year survival in resected patients receiving adjuvant radiotherapy was 16% vs 0% with resection alone.
In a report from the University of Amsterdam, 112 patients underwent resection of hilar cholangiocarcinoma. Of the 91 patients surviving postoperatively, 20 patients had no additional treatment, 30 patients EBRT only, and 41 patients combined EBRT and intraluminal brachytherapy. Patients receiving adjuvant radiotherapy experienced an improved median survival compared to those receiving no additional treatment (24 vs 8 months). The authors concluded that radiotherapy following resection of hilar cholangiocarcinoma improved survival, although there was no apparent benefit of intraluminal brachytherapy.
Investigators from the University of California at San Francisco described the outcome of 129 patients who underwent resection for bile duct carcinoma. Forty-five received EBRT and 22 received charged-particle radiation therapy. Median survival for surgery alone, surgery/EBRT and surgery/particle therapy was 6.5, 11, and 14 months, respectively.
In contrast to previous reports, a follow-up study from Johns Hopkins investigators detailed a prospective, nonrandomized analysis of patients with perihilar cholangiocarcinoma. Fifty patients underwent resection or palliative decompression for localized disease. Radiotherapy was delivered as EBRT alone or EBRT with intraluminal brachytherapy. For patients undergoing curative resection, no difference in median survival was seen whether or not patients received radiotherapy (20 months in both groups). Additionally, no significant difference in median survival was seen with the addition of radiation therapy in patients undergoing palliative surgery (8 vs 12.5 months). The authors concluded that postoperative radiation therapy did not improve survival.
However, a more recent report from John Hopkins described 34 patients with distal common bile duct cholangiocarcinoma treated with pancreaticoduodenectomy followed by adjuvant radiation therapy with concurrent and maintenance fluorouracil (5-FU)-based chemotherapy. Median survival was 37 months, with a 5-year survival rate of 35%. When compared to historical controls from the same institution treated with pancreaticoduodenectomy only (prior to the routine practice of adjuvant chemoradiation), patients receiving adjuvant therapy had a significantly longer survival (37 vs 22 months, P < .05).
No definitive conclusions as to the efficacy of postoperative radiotherapy can be drawn from these studies, although these and other data suggest improved local control and survival may be achieved with its use. A summary of postoperative EBRT studies is shown in Table 1.[1-23]
Even with the addition of radiation therapy and chemotherapy to surgery, the risk of local recurrence in cholangiocarcinomas remains high. This experience has prompted investigation of novel treatment approaches to enhance local control and survival. Although there is limited experience with neoadjuvant treatment in biliary carcinoma, this strategy has potential advantages. By postponing surgical resection until completion of chemoradiation, patients with malignancy that is rapidly progressive may avoid unnecessary surgery with potential morbidity. Secondly, preoperative therapy may facilitate tumor downstaging and potentially convert an unresectable tumor to resectable status. Theoretically, preoperative therapy may reduce the risk of tumor seeding and dissemination at the time of resection, as well as allow delivery of treatment to disease with an intact vasculature. This may improve the therapeutic effect of both chemotherapy and radiotherapy via improved drug delivery and better tumor oxygenation, which renders cells more sensitive to radiation. Additionally, the morbidity and delayed recovery time associated with extensive surgical procedures may preclude the timely delivery of postoperative therapy in a high percentage of patients.[24,25]
A report from M.D. Anderson Cancer Center described nine patients (five hilar and four distal common duct cholangiocarcinoma) treated with preoperative chemoradiation therapy. Patients received continuous-infusion 5-FU (300 mg/m2/d) during EBRT. No residual carcinoma was seen in the surgical specimens in three of nine patients, whereas the tumors of the remaining six patients showed a range of histologic responses. The margin-negative resection rate was 100% for the preoperative chemoradiation group, compared with 54% for the surgery-alone group (P < .01). Patients receiving preoperative treatment did not experience significant treatment-related complications.
Gerhards et al described 21 patients with proximal cholangiocarcinoma receiving low-dose preoperative irradiation of 10.5 Gy given over three fractions. None of these patients developed wound implantation, in contrast to a 20% rate of wound implantation in similar patients not receiving preoperative chemoradiation. At Duke University Medical Center, marginally resectable and selected resectable patients with extra-hepatic biliary ductal cancers have received preoperative chemoradiotherapy (EBRT and 5-FU via continuous infusion or capecitabine [Xeloda]), followed by laparotomy and resection when feasible.
1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006.
2. Piehler JM, Crichlow RW: Primary carcinoma of the gallbladder. Surg Gynecol Obstet 147:929-942, 1978.
3. Yee K, Shepperd B, Domreis J, et al: Cancers of the gallbladder and biliary ducts. Oncology (Williston Park) 16:939-949, 2002.
4. Daines WP, Rajagopalan V, Grossbard ML, et al: Gallbladder and biliary tract carcinoma: A comprehensive update, Part 2. Oncology (Williston Park) 18:1049-1068 (incl discussion), 2004.
5. Mahe A, Stampfli C, Romestang P, et al: Primary carcinoma of the gallbladder: Potential for external radiation therapy. Radiother Oncol 33:204-208, 1994.
6. Donohue JH, Stewart K, Menck H: The National Cancer Data Base Report on carcinoma of the gallbladder, 1989-1995. Cancer 83:2618-2628, 1998.
7. Todoroki T, Gunderson LL, Nagorney DM: Biliary tract IORT, in Gunderson LL, Willett CG, Harrison LB, et al (eds): Intraoperative Irradiation: Techniques and Results: Totowa, NJ, Humana Press, 1999.
8. Maibenco D, Smith J, Nava H, et al: Carcinoma of the gallbladder. Cancer Invest 16:33-39, 1998.
9. Kopelson G, Harisiadis L, Tretter P, et al: The role of radiation therapy in cancer of the extra-hepatic biliary system: An analysis of thirteen patients and a review of the literature of the effectiveness of surgery, chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2:883-894, 1977.
10. Schoenthaler R: Hepatobiliary carcinomas, in Leibel S, Phillips T (eds): Textbook of Radiation Oncology, 1st ed, pp 659-675. Philadelphia, WB Saunders, 1998.
11. Mahe M, Romestaing P, Talon B, et al: Radiation therapy in extrahepatic bile duct carcinoma. Radiother Oncol 21:121-127, 1991.
12. Hayes J, Sapozink M, Miller F, et al: Definitive radiation therapy in bile duct carcinoma. Int J Radiat Oncol Biol Phys 15:735-744, 1988.
13. Mittal M, Romestaing P, Iwatsuki S, et al: Primary cancers of extrahepatic biliary passages. Int J Radiat Oncol Biol Phys 11:849-854, 1985.
14. Alden M, Mohiuddin M: The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 28:945-951, 1994.
15. Gonzalez Gonzalez D, Gouma D, Rauws E, et al: Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma. Ann Oncol 10:215-220, 1999.
16. Czito B, Hurwitz H, Clough R, et al: Adjuvant external beam radiotherapy with concurrent chemotherapy following resection of primary gallbladder carcinoma: A 23-year experience. Int J Radiat Oncol Biol Phys 62:1030-1034, 2005.
17. Gonzalez Gonzalez D, Gerard J, et al: Results of radiation therapy in carcinoma of the proximal bile duct (Klatskin tumor). Semin Liver Dis 10:131-141, 1990.
18. Cameron J, Pitt H, Zinner M, et al: Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg 159:91-98, 1990.
19. Gerhards M, Vangulik T, Gonzalez Gonzalez D, et al: Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 27:173-179, 2003.
20. Schoenthaler R, Phillips T, Castro J, et al: Carcinoma of the extrahepatic bile ducts: UCSF experience. Ann Surg 219:267-274, 1994.
21. Pitt H, Nakeeb A, Abrams R, et al: Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 221:788-798, 1995.
22. Hughes M, Frassica D, et al: Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 59(suppl), 2005.
23. Treadwell T, Hardin W: Primary carcinoma of the gallbladder. The role of adjunctive therapy in its treatment. Am J Surg 132:703-706, 1976.
24. Sohn T, Yeo C, Cameron J, et al: Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567-579, 2000.
25. Spitz F, Abbruzzese J, Lee JE, et al: Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodectomy for adenocarcinoma of the pancreas. J Clin Oncol 15:928-937, 1997.
26. McMasters K, Tuttle T, Leach S, et al: Neoadjuvant chemoradiation enhances margin-negative resection rates for extrahepatic cholangiocarcinoma. Am J Surg 174:605-609, 1997.
27. Gerhards M, Gonzalez Gonzalez D, ten Hoopen-Neumann H, et al: Prevention of implantation metastases after resection of proximal bile duct tumors with pre-operative low dose radiation therapy. European J Surg Oncol 26:40-45, 2000.
28. Farley D, Weaver A, Nagorney D, et al: "Natural history" of unresected cholangiocarcinoma: Patient outcome after noncurative intervention. Mayo Clin Proc 70:425-429, 1995.
29. Grove M, Hermann R, Vogt D, et al: Role of radiation after operative palliation in cancer of the proximal bile ducts. Am J Surg 161:454-458, 1991.
30. Veeze-Kuijpers B, Merrwaldt J, Mameris J, et al: The role of radiotherapy in the treatment of bile duct carcinoma. Int J Radiat Oncol Biol Phys 18:63-67, 1990.
31. Crane C, McDonald K, Bauthty J, et al: Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 53:969-974, 2002.
32. Brunner T, Schwab D, Meyer T, et al: Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma: A retrospective analysis. Strahlentherapie Und Onkologie 180:751-757, 2004.
33. Foo M, Gunderson L, Bender C, et al: External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 39:929-935, 1997.
34. Fletcher M, Dawson J, Wheeler P, et al: Treatment of high bile duct carcinoma by internal radiotherapy with iridium-192 wire. Lancet 2:172-174, 1981.
35. Minsky B, Wesson M, Armstrong JG, et al: Combined modality therapy of extrahepatic biliary system cancer. Int J Radiat Oncol Biol Phys 18:1157-1163, 1990.
36. Minsky BD, Kemeny N, Armstrong JG, et al: Extrahepatic biliary system cancer: An update of a combined modality approach. Am J Clin Oncol 14:433-437, 1991.
37. Fields J, Emami B: Carcinoma of the extrahepatic biliary system-results of primary and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 13:331-338, 1987.
38. Johnson D, Safai C, Goffinet D, et al: Malignant obstruction jaundice: Treatment with external-beam and intracavitary radiotherapy. Int J Radiat Oncol Biol Phys 11:411-416, 1985.
39. Montemaggi O, Costamagna G, Dobelbower R: Intraluminal brachytherapy in the treatment of pancreas and bile duct carcinoma. Int J Radiat Oncol Biol Phys 32:437-443, 1995.
40. Eschelman D, Shapiro M, Bonn J, et al: Malignant biliary duct obstruction: Long-term experience with Gianturco stents and combined-modality radiation therapy. Radiology 200:717-724, 1996.
41. Fritz P, Brambs H-J, Schraube P, et al: Combined external beam radiotherapy and intraluminal high dose rate brachytherapy on bile duct carcinomas. Int J Radiat Oncol Biol Phys 29:855-861, 1994.
42. Takamura A, Saito H, Kamada T, et al: Intraluminal low-dose-rate Ir-192 brachytherapy combined with external beam radiotherapy in biliary stenting for unresectable extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 57:1357-1365, 2003.
43. Lu J, Bains Y, Abdel-Waheb M, et al: High-dose-rate remote afterloading intracavitary brachytherapy for the treatment of extrahepatic biliary duct carcinoma. Cancer J 8:74-78, 2002.
44. Iwasaki Y, Todoroki T, Fukao K, et al: The role of intraoperative radiation therapy in the treatment of bile duct cancer. World J Surg 12:91-98, 1988.
45. Busse P, Stone M, Sheldon T, et al: Intraopertive radiation therapy for biliary tract carcinoma: Results of a 5-year experience. Surgery 105:724-733, 1989.
46. Monson JR, Donohue JH, Gunderson LL: Intraoperative radiotherapy for unresectable cholangiocarcinoma-the Mayo Clinic experience. Surg Oncol 1:283-290, 1992.
47. Todoroki T, Ohara K, Kawamoto T, et al: Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 46:581-587, 2000.
48. Buskirk SJ, Gunderson LL, Schild S, et al: Analysis of failure after curative irradiation of extrahepatic bile duct carcinoma. Ann Surg 215:125-131, 1991.
49. Deziel D, Kiel K, Kranner T, et al: Intraoperative radiation therapy in biliary tract cancer. Amer Surg 54:402-407, 1988.
50. Moertel C, Childs D, Reitmeier R: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865-867, 1969.
51. Moertel C, Frytak S, Hahn R, et al: Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high-dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil) and high-dose radiation plus 5-fluorouracil. Cancer 48:1705-1710, 1981.
52. Kalser M, Elenberg S: Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899-903, 1985.
53. Morganti A, Trodella L, Valentini V, et al: Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int J Radiat Oncol Biol Phys 46:913-919, 2000.
54. McGinn C, Lawrence TS: Clinical results of the combination of radiation and fluoropyrimidines in the treatment of intrahepatic cancer. Semin Radiat Oncol 7:313-323, 1997.
55. Robertson J, McGinn C, Walker S, et al: Phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases. Int J Radiat Oncol Biol Phys 39:1087-1092, 1997.
56. Robertson J, Lawrence TS, Anderson J, et al: Long-term results of hepatic artery fluorodexoyuridine and conformal radiation therapy for primary hepatobiliary cancers. Int J Radiat Oncol Biol Phys 37:325-330, 1997.
57. Ben-Josef E, Normolle D, Ensminger W, et al: Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 23:8739-8747, 2005.
58. Flickinger J, Epstein A, Iwatzuki S, et al: Radiation therapy for primary carcinoma of the extrahepatic biliary system. Cancer 68:289-294, 1991.
59. Urego M, Flickinger J, Car B, et al: Radiotherapy and multimodality management of cholangiocarcinoma. Int J Radiat Oncol Biol Phys 44:121-126, 1999.
60. Heimbach J, Gores G, Haddock M, et al: Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis 24:201-207, 2004.